Scimed licenses AngioMedics' anti-restenosis catheter in overseas markets.
This article was originally published in The Gray Sheet
Executive Summary
SCIMED GAINS MARKETING RIGHTS TO RESTENOSIS RESISTANT ANGIOPLASTY SYSTEM from AngioMedics II, Inc. under a deal announced Jan. 10. In exchange for buying up to $5 mil. in AngioMedics II stock, Scimed gains rights to market the device in countries other than the U.S. AngioMedics has not decided whether it will market the device in the U.S. or enter an agreement with a domestic marketing partner.